## world's 1st aids cure/prevention! ##

27 September 2005
The Manager
Company Announcements Office
Australian Stock Exchange Ltd
4th Floor, 20 Bridge Street
SYDNEY NSW 2000.
ASX RELEASE
Test Results Confirm Citrofresh is Effective Against
Four Major Virus Types Including HIV & Avian
Retroscreen
Citrofresh International Ltd (CTF) is pleased to announce that its Citrofresh organic
bioflavonoid compound has been tested by Retroscreen Virology Laboratory against four
different RNA viruses.
In a landmark result, Retroscreen Virology confirmed that “Citrofresh exhibits significant
virucidal activity against all four viruses tested”.
The study concluded the efficacy of Citrofresh against both enveloped and non-enveloped
viruses and suggested that equal or less than 5% concentration and equal or less than 5
minutes contact time is sufficient to eliminate all of the viruses.
VIRUS NAME COMMON NAME TYPE OF VIRUS
HIV-1 Virus HIV/AIDS Double Stranded RNA Virus)
Human Influenza A
Virus
Influenza Enveloped Single Stranded RNA Virus
Urbani SARS Virus SARS Enveloped Single Stranded RNA Virus
Human Rhinovirus
Cause of Common
Colds
Non-Enveloped, Single Stranded RNA
Virus
Citrofresh International Ltd. ABN: 76 064 551 426 Sanitising The World For Your Protection
Results
Human Immunodeficiency Virus -1 (HIV-1)
HIV is one of the most serious viral diseases of our time, with an estimated 40 million people
infected with the virus. HIV/AIDS is the fastest growing threat to human development today.
The World Health Organization (WHO) reports that the number of women living with HIV has
risen in each region of the world over the past two years, with the steepest increases in East
Asia being 56%. The global AIDS epidemic killed 3.1m people in 2003. We believe that we can
now offer a global solution to reduce and eventually stop the spread of this disease using
Citrofresh.
A report issued in 2003 by the Centre for Infectious Disease and Control (“CDC”) stated:-
“that an ‘ideal’ microbicidal product would have to be effective against multiple STD’s,
including HIV. It should be safe to use several times daily, fast acting, acceptable to users,
affordable, colourless, odourless, easy to store and to use, easy to obtain, and available in a
variety of preparations, including with or without a contraceptive component. None of the
compounds currently in development meet these ideal standards and experts say it is unlikely
that any one product will meet them all. The immediate priority is to develop a microbicidal
product that would provide protection against HIV.”
The CDC further noted that the principal problem is the multitude of STD’s. Dr. Robert
Johnson, a medical epidemiologist with the Division of STD Prevention at the CDC notes that
“there isn't a single drug that can treat all STD’s. The viral agents cannot be treated. Coming
up with a regimen is problematic.”
The ability of Citrofresh to be both a broad spectrum biocide (including efficacy against HIV)
and to meet the ideal “criteria” as noted by the CDC provides Citrofresh with a unique market
opportunity. CTF will market a range of “Barrier Protection” products to be used in the first
instance for Men’s Health (post intercourse spray or lotion) and subject to the results of trials
on efficacy; we will then introduce a vaginal biocide to the market.
In terms of potential market application the following United Nations view highlights the need
for an effective biocide, Citrofresh would fit this criteria: -
�� Worldwide, an estimated 250 million new cases of STDs occur annually.
�� Postcoital STD treatment could also be helpful for couples who use condoms as a means
of STD prevention but experience condom breakage or slippage, similar to emergency
contraception when used to prevent pregnancy when a couple experiences condom
failure.
�� In reality, the use of Citrofresh as a postcoital application will act as an “invisible
condom” for the prevention of STD’s including HIV. This is a significant development
for the global health markets and for communities that through social custom, religious
belief or sexual practice; do not use condoms for disease protection.
�� It should be further noted that with the withdrawal of Nonoxly-9 from the market due
to concerns that it increases susceptibility to HIV and STD’s, a huge market gap has
appeared. CTF intends to take full advantage of this market opportunity.
The ability to use Citrofresh as a postcoital application will have a significant impact on
reducing the transmission of HIV and STD’s. The CDC and the WHO now acknowledge that the
development of an HIV vaccine has been problematic and that in the medium term the only
mechanism for controlling the spread of AIDS will be an effective biocide.
Citrofresh International Ltd. ABN: 76 064 551 426 Sanitising The World For Your Protection
To secure a quick an effective path to market, Citrofresh is undertaking discussions with
several market leaders for the distribution of the Men’s Health product range. Collaboration is
also being sought by CTF to undertake further trials for applications in the Women’s Health
market segment i.e. a vaginal biocide.
Human Influenza A-Type Virus
Human Influenza A Type Virus (including Avian Influenza) is a contagious disease which rapidly
spreads around the world in seasonal epidemics. Major genetic changes in the virus have
caused three influenza pandemics in the 20th century, killing many millions of people. The A
type virus, which is most likely to cause epidemics and pandemics is divided into subtypes. The
current subtypes found in humans are the H1N1 and H3N2 strains.
Of major concern to governments and health authorities is the potential for Avian Influenza
H5N1 to mutate (or undergo antigenic shift) into an infectious human strain to which people
are not immune. The strain has already killed 64 people in four Asian countries since late 2003
and has led to the slaughter of millions of birds and poultry flocks world-wide.
The WHO believes a worldwide pandemic from a mutated H5N1 strain could kill anything from
seven to 100 million people. Previous pandemics include the 1919 Spanish flu which killed up
to 40 million people and two others in 1957 and 1968, killing four million and two million
people respectively. Government organizations are working around the clock to prepare for the
potential global outbreak. Again, Citrofresh can provide a non-toxic alternative to the current
toxic remedies to alleviate and stop the spread of this virus.
In addition to studies already completed in South Africa, the Retroscreen report provides
further verification to the efficacy of Citrofresh against virulent A type strains.
The main strategy for counteracting the spread of avian is decontamination at the source of
infected areas. Citrofresh is a safe, non-hazardous and effective solution to decontaminate
where avian or other contamination problems are present. Citrofresh has clear advantages
over chemical disinfectants currently in the marketplace. The company expects significant
growth in the disinfectant markets and is continually assessing distribution opportunities worldwide
with positive results. This is a multi-billion dollar market and the company is now
implementing strategies to achieve significant market share in this arena.
Severe Acute Respiratory Syndrome (SARS)
Severe Acute Respiratory Syndrome (SARS) is the first major new infectious disease of the
21st Century. Currently, there are no vaccines available against this virus. The Urbani strain of
Severe Acute Respiratory Syndrome (SARS) virus belongs to the family of Coronaviridae. SARS
is a viral respiratory illness and the antiviral drugs available on the market have limited
effectiveness. The Urbani strain refers to the most common strain identified by Dr. Carlo
Urbani, the WHO scientist who first identified the virus in Hanoi (Vietnam) and subsequently
died of SARS.
SARS was first reported in Asia in late 2002. Over the next few months, a global outbreak
occurred where the illness spread to more than two dozen countries throughout the continents
of Asia, North America, South America and Europe. According to the World Health
Organization, a total of 8,098 people worldwide became sick with SARS during the initial
outbreak. Of these, 774 died.
Again, the main strategy for counteracting the spread of SARS was containment and isolation.
Citrofresh broad-spectrum disinfectant provides the solution for organizations to prevent the
re-emergence of this disease.
Citrofresh International Ltd. ABN: 76 064 551 426 Sanitising The World For Your Protection
Human Rhinovirus
Human Rhinoviruses (from the Greek Rhin, meaning “nose”) are one of the families of viruses
that cause the common cold. It is estimated that about one half of "colds" are caused by
rhinovirus infections. There are a limited number of antibiotic drugs available to treat the
secondary infection caused by this virus.
In terms of identifying further investigation into potential in-vivo (in the body) use of
Citrofresh, Retroscreen has suggested that Citrofresh “could be further studied for possible
uses as a nasal spray to prevent or treat infection of both Human Rhinovirus and Urbani SARS
virus.”
About Retroscreen
Retroscreen Virology is Europe’s leading contract virology research company and specializes in
the development of antiviral compounds and vaccines to fight viral diseases worldwide. The
recent report and study were commissioned to determine the concentrations and spectrum of
anti-viral efficacy of Citrofresh.
Conclusion:
Citrofresh is an effective virucidal agent that can target HIV, Urbani SARS, Human Influenza A
and Human Rhinovirus. This reinforces both Derm-e-San and Citrofresh generally as world
leading products in this market.
The company considers the results of the Retroscreen study, a major milestone in its strategy
of further validating the efficacy of its product. Emergency disease control and prevention is a
primary objective of government organizations world-wide and Citrofresh provides a nonhazardous,
non-toxic and effective solution that deal with these problems.
The business of preventing the spread of viruses is a multi-billion dollar market. CTF intends to
take full advantage of this opportunity by delivering non-toxic alternatives and providing a safe
solution for the world’s future.
For Further enquiries:
Ravi Narain, Ron Gajewski,
Managing Director and Chief Executive Officer, Non-Executive Chairman,
(03) 5272 3013 (08) 9240 2448
Dated 27 September 2005
END

wrxsti